Abstract

Pulmonary arterial hypertension (PAH) is characterised by an increase in mean pulmonary arterial pressure which almost invariably leads to right heart failure and premature death. More than 70% of familial PAH and 20% of idiopathic PAH patients carry heterozygous mutations in the bone morphogenetic protein (BMP) type 2 receptor (BMPR2). However, the incomplete penetrance of BMPR2 mutations suggests that other genetic and environmental factors contribute to the disease. In the current study, we investigate the contribution of autophagy in the degradation of BMPR2 in pulmonary vascular cells. We demonstrate that endogenous BMPR2 is degraded through the lysosome in primary human pulmonary artery endothelial (PAECs) and smooth muscle cells (PASMCs): two cell types that play a key role in the pathology of the disease. By means of an elegant HaloTag system, we show that a block in lysosomal degradation leads to increased levels of BMPR2 at the plasma membrane. In addition, pharmacological or genetic manipulations of autophagy allow us to conclude that autophagy activation contributes to BMPR2 degradation. It has to be further investigated whether the role of autophagy in the degradation of BMPR2 is direct or through the modulation of the endocytic pathway. Interestingly, using an iPSC‐derived endothelial cell model, our findings indicate that BMPR2 heterozygosity alone is sufficient to cause an increased autophagic flux. Besides BMPR2 heterozygosity, pro‐inflammatory cytokines also contribute to an augmented autophagy in lung vascular cells. Furthermore, we demonstrate an increase in microtubule‐associated protein 1 light chain 3 beta (MAP1LC3B) levels in lung sections from PAH induced in rats. Accordingly, pulmonary microvascular endothelial cells (MVECs) from end‐stage idiopathic PAH patients present an elevated autophagic flux. Our findings support a model in which an increased autophagic flux in PAH patients contributes to a greater decrease in BMPR2 levels. Altogether, this study sheds light on the basic mechanisms of BMPR2 degradation and highlights a crucial role for autophagy in PAH. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Highlights

  • Pulmonary arterial hypertension (PAH) is characterised by an increase in mean pulmonary arterial pressure, pulmonary capillary wedge pressure (15 mmHg), and pulmonary vascular resistance [1]

  • To investigate the mechanisms by which endogenous BMPR2 is degraded in the context of PAH, pulmonary artery endothelial cells (PAECs) were treated with the lysosomal inhibitors bafilomycin A1 (BafA1) and HCQ and with the proteasome inhibitors MG-132 and BTZ

  • To confirm that the increase in BMPR2 protein levels was due to a block in lysosomal degradation rather than an increase in mRNA levels, RT-qPCR analysis of BMPR2 was performed in PAECs after BafA1 treatment

Read more

Summary

Introduction

Pulmonary arterial hypertension (PAH) is characterised by an increase in mean pulmonary arterial pressure (greater than 25 mmHg at rest), pulmonary capillary wedge pressure (15 mmHg), and pulmonary vascular resistance (greater than 3 Wood units) [1]. The classification of PAH comprises non-hereditary or idiopathic PAH (iPAH) and hereditary PAH, which is mostly related to heterozygous germline mutations in BMPR2 [5,6,7,8]. BMPR2 encodes for the bone morphogenetic protein (BMP) type 2 receptor, which belongs to the transforming growth factor β (TGF-β) family. It is a transmembrane serine/threonine kinase receptor, which upon BMP binding mediates the activation of intracellular Smad downstream effectors. 20% of iPAH patients carry heterozygous mutations that compromise BMPR2 function [9]. Among PAH patients, those with BMPR2 mutations develop a more severe disease with worse survival [10]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call